MG-262 (Z-Leu-Leu-Leu-B(OH)2): Reversible Proteasome Inhibitor for Cell Cycle and Apoptosis Research

Executive Summary: MG-262 is a cell-permeable, reversible proteasome inhibitor with an IC₅₀ of 122 nM, targeting the chymotryptic activity of the 26S proteasome under physiological conditions [APExBIO product page]. It induces cell cycle arrest and apoptosis by modulating retinoblastoma phosphorylation and activating caspase-3 and PARP pathways (Thorne et al., 2023). MG-262 inhibits osteoclast differentiation in vitro in a dose-dependent manner. It is insoluble in water but highly soluble in DMSO and ethanol, requiring fresh preparation due to solution instability. As a research tool, it provides mechanistic insight into the ubiquitin-proteasome system for cancer, inflammation, and neurodegenerative disease models.

Biological Rationale

The ubiquitin-proteasome system (UPS) orchestrates selective protein degradation and is central to cell cycle regulation, apoptosis, and immune signaling [DOI]. Proteasome inhibitors like MG-262 allow targeted manipulation of UPS activity, providing a means to study protein turnover and downstream effects on cell viability. MG-262’s reversible inhibition is critical for dissecting transient versus sustained UPS blockade in cellular models. The structure—a peptide backbone with a terminal boronic acid—confers high selectivity for the proteasome’s chymotryptic site, enabling precise experimental control [APExBIO]. This selectivity is essential in research on malignancy, inflammatory signaling, and programmed cell death, where proteasome dysregulation often plays a pivotal role.

Mechanism of Action of MG-262 (Z-Leu-Leu-Leu-B(OH)2)

MG-262 acts as a competitive, reversible inhibitor of the 20S core particle’s chymotryptic-like activity. The boronic acid group covalently but reversibly binds the active site threonine of the proteasome’s β5 subunit, blocking substrate access and degradation. This inhibition leads to accumulation of ubiquitinated proteins, disruption of cell cycle progression, and induction of apoptosis via both intrinsic (mitochondrial) and extrinsic pathways. MG-262 is cell-permeable, efficiently entering a broad range of mammalian cells. The compound’s reversibility allows for temporal studies and washout experiments, distinguishing it from irreversible inhibitors [Related: PS341.com].

Evidence & Benchmarks

• MG-262 exhibits an IC₅₀ of 122 nM for proteasome chymotryptic activity in cell-based assays at 37°C, pH 7.4 (https://www.apexbt.com/mg-262.html).
• Reduces cell viability and induces growth arrest in nasal mucosa and polyp fibroblasts by inhibiting DNA replication and retinoblastoma phosphorylation (https://doi.org/10.1371/journal.pone.0286783).
• Upregulates cell cycle inhibitors p21 and p27, leading to G1/S arrest in multiple cell lines (https://doi.org/10.1371/journal.pone.0286783).
• Triggers mitochondrial membrane potential loss, caspase-3 activation, and PARP cleavage, hallmarks of apoptosis (https://doi.org/10.1371/journal.pone.0286783).
• MG-262 inhibits osteoclast differentiation in vitro in a dose-dependent fashion, validated by TRAP staining and resorption pit assays (https://www.apexbt.com/mg-262.html).
• In vivo, intravenously administered MG-262 reduces proteasome activity in multiple organs within 1–4 hours post-injection, confirming systemic bioavailability (https://www.apexbt.com/mg-262.html).
• MG-262 reversibly inhibits proteasome activity; upon compound removal, chymotryptic activity is restored within 2–6 hours in cultured cells (https://ps-341.com/index.php?g=Wap&m=Article&a=detail&id=15191).

This article extends prior coverage on PS341.com by providing new, peer-reviewed evidence on MG-262’s effects on cell cycle regulators and apoptosis pathways. It also clarifies protocol parameters compared to MG132.com, with updated solubility and stability data. For a translational perspective, see Oprozomib-ONX-0912-PR-047.com, which we update here with in vivo benchmarks and application limits.

Applications, Limits & Misconceptions

Research Applications

• Cell cycle arrest studies: MG-262 is used to dissect checkpoints and cyclin/CDK regulation by proteasome function.
• Apoptosis research: Investigates caspase activation, mitochondrial membrane integrity, and PARP cleavage following proteasome inhibition.
• Osteoclast differentiation inhibition: Used in bone biology to model the impact of proteasome function on osteoclastogenesis.
• Modeling cancer, inflammatory, and neurodegenerative diseases where UPS dysregulation is implicated.
• Screening for pathway-specific inhibitors or combination therapies in preclinical systems.

Common Pitfalls or Misconceptions

• MG-262 is not water-soluble: The compound is insoluble in water; inappropriate solvents can cause precipitation and assay failure.
• Stability issues: MG-262 is unstable in solution and must be freshly prepared before use; prolonged storage in solvent degrades activity.
• Reversibility: Unlike irreversible inhibitors, MG-262’s effects can be reversed by washout; misinterpretation may occur if this is not accounted for in protocol design.
• Not selective for non-proteasomal proteases: MG-262’s boronic acid group is specific to proteasome β5 sites and does not broadly inhibit other serine or cysteine proteases.
• In vivo dosing limitations: Systemic administration may affect multiple organs; tissue-specific targeting requires additional validation.

Workflow Integration & Parameters

• Solubility: ≥24.57 mg/mL in DMSO, ≥96.4 mg/mL in ethanol; insoluble in water.
• Storage: Store solid at -20°C, protected from light and moisture. Prepare fresh solutions before use.
• Working concentrations: Typical in vitro dosing ranges from 10 nM to 1 μM, depending on cell type and endpoint.
• Controls: Include vehicle-only and proteasome activity recovery controls (washout) to validate reversibility.
• Companion assays: Use with cell viability (MTT/XTT), immunoblotting for ubiquitinated proteins, and caspase activity assays for endpoint validation.
• For details and purchase, see the MG-262 (Z-Leu-Leu-Leu-B(OH)2) A8179 kit at APExBIO.

Conclusion & Outlook

MG-262 (Z-Leu-Leu-Leu-B(OH)2) is a rigorously benchmarked, reversible, and cell-permeable proteasome inhibitor. It remains the gold standard for dissecting UPS function, cell cycle control, and apoptosis in a wide array of disease models. Researchers are advised to adhere to validated protocols regarding solubility and compound stability. Ongoing studies continue to expand its application in translational pipelines for cancer, inflammation, and neurodegeneration. APExBIO provides high-purity MG-262 and technical support for experimental design. For further reading, compare with recent advances in reversible proteasome inhibition at MG132.com.